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Abstract: In this study, sodium clodronate, a well-known therapeutic agent from the family
of bisphosphonates (BPs), is incorporated in a biomimetic calcium phosphate (CaP) coating,
previously formed on the surface of a starch-based biomaterial by a sodium silicate
methodology, as a strategy to develop a site-specific drug delivery system for bone tissue
regeneration applications. The effects on the resulting CaP coatings were evaluated in terms of
morphology, chemistry, and structure. The dissolution of Ca and P from the coating and the
release profiles of sodium clodronate was also assessed. As a preliminary approach, this first
study also aimed at evaluating the effects of this BP on the viability of a human osteoblastic
cell line since there is still little information available on the interaction between BPs and this
type of cells. Sodium clodronate was successfully incorporated, at different doses, in the
structure of a biomimetic CaP layer previously formed by a sodium silicate process. This
type of BPs had a stimulatory effect on osteoblastic activity, particularly at the specific
concentration of 0.32 mg/mL. It is foreseen that these coatings can, for instances, be
produced on the surface of degradable polymers and then used for regulating the
equilibrium on osteoblastic/osteoclastic activity, leading to a controlled regenerative effect
at the interface between the biomaterial and bone. ' 2009 Wiley Periodicals, Inc. J Biomed Mater
Res Part B: Appl Biomater 92B: 55–67, 2010
Keywords: biodegradable polymers; starch; biomimetic coating; calcium phosphate; sodium
silicate; bisphosphonate; drug therapy
INTRODUCTION
Although remarkable progresses have been made to pro-
duce superior bone-like materials, the right balance
between surface and bulk properties is still to be achieved.
At present, one of the most interesting solutions to this
problem is to use calcium phosphates (CaPs) as coatings on
the surface of biomaterials. In addition, due to their osteo-
genic potential, CaP layers can be used as drug-carrier sys-
tems in bone tissue engineering applications.1,2 Recently,
CaP layers were deposited on the surfaces of metal
implants under highly unphysiological conditions. There-
fore, it was not possible to coat polymeric substrates or to
incorporate a bioactive agent. Plasma spraying, for exam-
ple, is a commercially available technique in which high
processing temperatures are used.3–7
At present, it is possible to produce CaP layers under
physiological conditions of temperature, pH, and pressure,
using the so-called biomimetic process.8–15 As a result,
there are new opportunities for applying this type of coat-
ings in the field of tissue engineering, as a way to enhance
cell adhesion and proliferation and extracellular matrix
production. On the other hand, new possibilities for incor-
porating bioactive molecules, such as synthetic drugs or
proteinaceous osteoinductive molecules, are being consid-
ered.2 Because of the slow, but definite, degradation of
CaPs, as well as their high hydrophilicity,16 they can be
very suitable to serve as carriers for these molecules.
Research envisioning CaP coatings as carrier systems
for the release of therapeutic molecules is still scarce, but
its potential have captured the attention of some groups in
the recent years. For example, antibiotic loading into CaP
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coatings on bone-replacement materials is a clinically rele-
vant concept in the setting of total joint arthroplasty and
has been addressed recently. Radin et al.17 have accom-
plished the loading of vancomycin by immersion of
ceramic-coated discs in vancomycin-containing simulated
physiological solution. In a study performed by Campbell
et al.,18 chlorhexidine was incorporated into an apatite coat-
ing by placing the substrate into various chlorhexidine solu-
tions in between mineralization cycles. CaP coatings
containing tobramycin were produced by Stigter et al.19 on
titanium alloy (Ti6Al4V) implants, using a biomimetic
approach. Although the options for creating a delivery sys-
tem in these coatings can be numerous, the affinity of a
specific molecule to the CaP crystals as well as its size,
charge, or conformation, are crucial features for an effec-
tive incorporation. In fact, some of these agents, because
of their chemical structure or conformation, can only
be adsorbed superficially, on preformed layers. Such
superficially adsorbed molecules are sometimes released
too rapidly within a biological milieu to be effective in
their therapeutic/osteoinductive capacity.
Bisphosphonates (BPs) are an important family of drugs
in various bone- and calcium-related pathologies, such as
cancer,20 hypercalcemia,21 Paget’s disease,22 or osteoporo-
sis.20–26 The affinity of BPs to bone mineral hydroxyapatite
(HA) is the basis for their use as inhibitors of bone resorp-
tion.25,26 They are pyrophosphate (P!!O!!P) analogs in
which the oxygen in the P!!O!!P has been replaced by a
carbon to yield a P!!C!!P backbone. Substitutions on the
carbon give rise to a large family of compounds with dif-
ferent properties and potencies, which are determined by
the nature of the side chains.26 The physicochemical effects
of BPs include binding strongly to the CaP crystals and in-
hibiting their growth, aggregation, and dissolution.25–27
Their biological effects in calcium-related disorders are due
to the direct interaction with osteoclasts28 and/or osteo-
blasts.29 It is now generally accepted that BPs inhibit osteo-
clast activity.23–25,29 However, the major drawback of the
clinically used BPs is their pharmacokinetics and poor oral
absorption from the gastrointestinal tract, which is typically
less than 1%.25,26 In addition, BPs have been associated
with adverse gastrointestinal effects in humans.30 The
attempts to improve the bioavailability of BPs had only
very limited success because of a lack of marked improve-
ment of adsorption and/or side effects.30 The challenge for
novel drug delivery systems is to achieve improved bioa-
vailability and safety. In addition to oral administration,
different strategies have been proposed over the last years,
such as nasal delivery31 and subcutaneous32–34 or intramus-
cular injection.35
In addition to being used in the treatment of the patholo-
gies described earlier, it has been also discovered36–38 that
BPs can be beneficial when administrated after bone
replacement, decreasing the primary failure mode of total
hip arthroplasty, which is aseptic loosening following peri-
implant osteolysis. Nevertheless, this effect could be
improved if the time delay for the BP to reach the bone–
implant interface could be reduced. In this case, a localized
delivery of the drug could have a favorable effect to pro-
duce a more stable and integrated interface between the
implant and the bone at the early stage of implantation,
when a significant bone loss can occur.39 In fact, this was
already attempted with success in several studies using
different BPs.39–42 For example, Kajiwara et al.40 have
treated calcium ion–implanted titanium implants with
pamidronate, which significantly accelerated new bone for-
mation in a rat tibia. Yoshinari et al.41 have studied the
effect of the same BP incorporated in a plasma-sprayed
HA-coated titanium dental implant in beagle mandibular
bone, increasing the bone–implant contact area. Recently,
Peter et al.42 have grafted zoledronate to plasma-sprayed
HA coating of titanium implants that were then inserted in
rat condyles. A positive concentration-dependent effect was
observed on the peri-implant bone density and on different
histomorphometric parameters.
Because of its reported effects on bone, one can envi-
sion that to incorporate a BP in a bone-like CaP-coated
biodegradable scaffold can be a very promising strategy for
designing a site-specific drug delivery system in a tissue
engineering approach, by locally enhancing tissue integra-
tion and regeneration. In this study, sodium clodronate, a
well-known BP, was physically incorporated at different
doses in a CaP coating, previously formed on the surface
of a starch-based biomaterial by a sodium silicate method-
ology. The effects on the resulting CaP coatings were
evaluated in terms of morphology, chemistry, and structure.
The release profile of the drug and the stability of the coat-
ings were assessed at different physiological environments.
As a preliminary approach, this study also aimed at screen-
ing the ideal sodium clodronate dose to be incorporated in
the CaP coatings, which is able to elicit positive effects on
the viability, growth, and function of a human osteoblastic-
like cell line. In fact, there is still little information
available on the interaction between BPs and this type of
cells.
MATERIALS AND METHODS
Preparation of the Samples
As a natural polymer with rather interesting properties,43–45
starch exhibits a great potential to be used in biomedical
applications. The studied material is based on a blend of
starch and ethylene vinyl alcohol (SEVA-C). The blend
contains around 50% starch by weight, while the copoly-
mer discloses a composition of 60/40 mol/mol. Compact
samples were produced by injection molding on a Klockner
Desma FM-20, using a nozzle temperature of 1708C. All
the samples were shaped into the form of disks with a
diameter of 10 mm. Further information on the properties
of starch-based polymers and its potential for biomedical
applications may be found elsewhere.43–46
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Sodium Silicate Methodology
To produce the bioactive coatings, a commercially avail-
able sodium silicate gel from Sigma-Aldrich
(Na2SiO3"H2O, containing #14% NaOH and #27% SiO2,
pH 13 was used). The sodium silicate gel was used with
concentration and SiO2/Na2O molar ratio as received.
15
The viscosity of the gel is 6 3 1022 Pa.s21. This high
viscosity allowed for the impregnation other than up-
taking the gel into the polymer, which would affect the
mechanical and degradation behavior of the material. The
materials (SEVA-C disks with a diameter of 10 mm)
were ‘‘impregnated’’ for 24 h with the gel, in a con-
trolled atmosphere (23 6 18C; 55% RH). After this
treatment, the gel with the samples was diluted with
50% vol. of distilled water and stirred for 5 min. This
procedure was aimed at diminishing the viscosity of the
gel to produce a homogeneous and thin layer of vitrified
sodium silicate in the surface of the materials. The sam-
ples were then removed from the solution and dried in a
controlled atmosphere (23 6 18C; 55% RH).
Apatite Formation
An aqueous solution was prepared comprising all major
inorganic ions present in human blood plasma and present-
ing its approximate ion concentration, to promote in vitro
apatite formation. The different salts were dissolved in
deionized H2O, and the pH was adjusted to neutral using
tris(hydroxymethyl)aminomethane and hydrochloric acid.
This simulated body fluid (SBF) solution was developed by
Kokubo et al.11
The treated samples were first soaked in SBF to nucleate
the CaP layer, and after 7 days, soaked in another solution,
with ion concentrations 1.53 SBF for allowing this layer
to grow. The solutions were renewed every 2 days during
the coating process, which lasted for 14 days. The average
thickness of the CaP layers formed by this methodology is
#2.5 lm (measured from the basis of the CaP nuclei to the
interface, according to a previously developed method47).
Incorporation of Sodium Clodronate
BPs are stable analogs of pyrophosphate in which the
P!!O!!P structure is replaced by a P!!C!!P structure.
Side chains R1 and R2 are attached to the geminal carbon
atom. The BP used in this study was a sodium clodronate
in which R1 and R2 are replaced by chloride. The structure
of this drug is shown in Figure 1.48
Sodium clodronate (dichloromethylene-BP) is one of the
best documented BP that is used effectively in medical
applications.48 In the literature, the ideal concentration of
this BP for inducing a positive effect in bone cells varies
from study to study. Therefore, we have chosen two lower
concentrations that are considered to be in the therapeutic
range48 and two higher concentrations to scale up the
effects of this BP in the structure of the CaP coating so
that could be detectable by infra red and x-ray spectroscop-
ies. Solutions of 0.064, 0.32, 8, and 16 mg/mL of sodium
clodronate (Sigma-Aldrich) were prepared with the pH
adjusted to 7.4 using NaOH (1 M). Aliquots of 50 lL of
each solution were added to the coated disks left for 3 h,
followed by drying at 608C. This procedure has been previ-
ously reported elsewhere.49 The effective concentration of
the BP in the coated samples is approximately as follows:
0.004, 0.02, 0.5, and 1 mg/cm2.
Structural and Morphological Characterization
The morphological characterization was performed by
scanning electron microscopy (SEM) analysis in a
LEICA Cambridge S360, United Kingdom. All the sam-
ples were coated with a thin film of carbon, by ion sput-
tering, before any observation. The electron beam energy
was 15 keV. Energy dispersive spectroscopy (EDS) was
performed qualitatively in a Rontec spectrometer, to
obtain the compositional profiles of the CaP layers incor-
porating different amounts of sodium clodronate. Fourier
transform infrared spectroscopy with attenuated total
reflectance (FTIR-ATR) was performed, aiming at detect-
ing any type of chemical modification on the samples
chemical structure. The acquisition was performed in
transmittance mode from 4000 to 500 cm21. All spectra
were recorded using 64 scans and 2 cm21 resolution in
an FTIR spectrophotometer (Perkin–Elmer 1600 Series).
Thin-film x-ray diffraction (TF-XRD; Philips X’Pert
MPD, The Netherlands) was used to identify the crystal-
line phases present in the CaP layers formed during the
immersion in SBF and after incorporating sodium clodro-
nate. The data collection was performed by 2y
scan method with 18 as incident beam angle using CuKa
X-ray line and a scan speed of 0.058/min in 2y.
Mechanical Behavior
Microhardness tests are usually regarded as a convenient
means of investigating the mechanical properties of mate-
rials in a localized and nondestructive manner. Micro-
hardness measurements have been used, herein, to study
the differences and correlation between the composition
and the surface or coatings in different kinds of samples.
The motivations of such measurements are to probe the
mechanical environment that the cells will feel when
in contact with the material, and to evaluate the influ-
ence of the presence of the drug in the coating in its
Figure 1. Chemical structure of sodium clodronate.48
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mechanical properties. A Leica VMHT30 equipment was
used to measure the microhardness of the samples at
room temperature (#208C), using a Vickers diamond pyr-
amid indented (included angle a 5 1368C). The micro-
hardness, Hv, was calculated from the residual projected
diagonal impression, using Hv 5 1.854 F/d
2 equation,
where d is the mean diagonal length of the indentation
in millimeter and F the applied force in Newton. A load
of 9.807 mN was applied during 10 s in all tests. These
conditions were chosen for getting measurements only at
level of the coating, avoiding the bulk of the substrate
samples. Fifteen measurements at randomly selected
places around coating of each sample were taken in
each condition. The same procedure was followed for the
samples’ substrate.
Dissolution Behavior
To try to predict the behavior of the CaP coating when fac-
ing the biological milieu is of extreme importance. How-
ever, to design a method capable of fully replicating it is
extremely difficult, considering the complexity of the bio-
logical fluids, going from minerals to proteins, enzymes,
and cells. In vitro dissolution tests, although far from the
ideal method, can give some insights on the stability of the
materials before implantation. In fact, because these studies
are performed in solution, they always simulate the worst
case low-end service environment.
Dissolution tests were performed on the coated samples
before and after loading with increasing doses of sodium
clodronate. Two different media were used in this study,
according to the International Standard ISO/DIS 10993-14
procedure and are presented in Table 1.
Solution 1 simulates, in a very simplistic way, the
in vitro physiological environment. Solution 2 is aimed at
reproducing the worse predictable scenario in which the
bone is resorbed due to osteoclastic activity. The coated
disks, incorporating different amounts of sodium clodro-
nate, were immersed in a volume of 5 mL of each solution.
Two replicates of each condition were studied. The experi-
ment was performed at 378C for periods up to 15 days.
Aliquots of 2 mL were removed at different periods and
replaced by the same volume of fresh solution. The
obtained samples were analyzed by induced coupled
plasma emission spectroscopy for the quantification of Ca
and P. The final cumulative concentration values were cal-
culated according to the following equation:
X
½Vn ! ðVn!1 &2=5Þ(n ð1Þ
Vn – volume aliquoted;
Vn21 – subsequent volume aliquoted;
Sodium Clodronate Release Studies
The release of sodium clodronate from the CaP coatings in
the previously described solutions was studied. The ana-
lyzed solutions and periods of time were the same in which
Ca and P were quantified. The release of the drug was
monitored by means of high-permeation liquid chromatog-
raphy (HPLC). The analysis was performed by using a
mixture (60:40) of methanol/aqueous solution of PIC A (a
solution of tetrabutylammonium hydrogen sulfate in water,
supplied by Waters) as the mobile phase and a flow rate of
1 mL/min. The system consisted of a Perkin–Elmer LC-
250 pump, an UV/vis detector Perkin–Elmer LC-95, and a
Waters lBoundapak C-18 column of 3.9 3 300 mm. Mea-
surements were made at 204 nm. Under these conditions,
TABLE I. Solutions Used in the Dissolution Studies
Solution No. Description
pH
(at 378C)
1 Simulated Tris–HCl solution 7.4
2 Acidic buffered solution
(simulating osteoclastic activity)
3
Figure 2. HPLC release profiles of sodium clodronate in (a) a
solution buffered to pH 7.4 and (b) a solution buffered to pH 3.
58 OLIVEIRA ET AL.
Journal of Biomedical Materials Research Part B: Applied Biomaterials
sodium clodronate presented a retention time of 2.31 and
2.35 min in pH 5 7.4 and pH 5 3, respectively.
The obtained profiles for each solution are presented in
Figure 2.
Release studies were performed from discs loaded with
8 mg/mL solutions of sodium clodronate, which provided
an effective concentration of 0.4 mg of drug per coated
disk. Discs prepared with lower concentration of drug (0.32
and 0.064 mg/mL) were not evaluated because they are
below the detection limit of the HPLC equipment. The
effective concentration loaded was 0.4 mg per coated disk,
which is the result of a 50-lL aliquot of a solution
with concentration 8 mg/mL. The results were plotted in
accordance with Eq. (1).
Preliminary Evaluation of Cell Adhesion and Proliferation
To study the morphology, attachment, and proliferation of
osteoblast-like cells over precalcified loaded SEVA-C
surfaces, a human osteoblast-like cell line (SaOs-2)
obtained from the European Collection of Cell Cultures
was selected. Dulbecco’s modified eagle’s medium
(Sigma), supplemented with 10% fetal bovine serum (FBS,
Biochrome, Germany) and 1% antibiotic/antimycotic solu-
tion (Sigma) was used as cell incubation medium, and
growth to confluence in controlled atmosphere conditions
(378C, 5% CO2, 100% humidity). Detachment of confluent
low passage cells was performed using 0.25% trypsin/
EDTA solution (Sigma). Subsequently, osteoblast-like cells
were cultured over samples in a concentration of 3.3 3 104
cell/mL and incubated for 3, 5, and 7 days in controlled
atmospheric conditions. Tissue culture grade polystyrene
was used as control and replicates were prepared. After
each incubation period, samples were washed with phos-
phate-buffered saline (Sigma) solution and fixed in gluteral-
dehyde 2.5% (v/v) for observation by means of scanning
electronic microscopy. After fixation, samples were dehy-
drated in crescent ethanol concentrations (50, 70, 90, and
100%), air dried, and sputter coated with gold.
Cell viability was measured through the MTS test, using
the CellTiter 961 AQueous One Solution from Promega,
which is based on bioreduction of a substrate (MTS) into a
brown product by dehydrogenase enzymes in metabolically
active cells, and it is commonly used for cell viability eval-
uation. Cells were then incubated for 3 h at 378C in a
humidified atmosphere containing 5% CO2. At this time,
optical density (OD) was measured with a plate reader at
490 nm. The mean OD value obtained for the positive
control (cell seeded on culture plate without any coating)
was considered as 100% metabolic activity.
RESULTS
Morphology, Crystallinity, and Chemical Structure of the
CaP Coatings
The effect of the incorporation of different doses of sodium
clodronate on the morphology, crystallinity, and chemical
structure of the biomimetic coatings was evaluated using
SEM/EDS, TF-XRD, and FTIR-ATR techniques. In Figure
3 is presented the morphology of the CaP coatings grown
on the surface of SEVA-C samples before and after a
treatment with sodium clodronate at 8 mg/mL. The
Figure 3. SEM micrographs performed on the apatite coatings grown on the surface of SEVA-C sam-
ples (a,b) before and (c,d) after the treatment with 8 mg/mL of sodium clodronate.
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corresponding EDS spectra showing the evolution of the
elemental composition are presented in Figure 4.
The use of sodium silicate biomimetic coating method-
ology resulted in the formation of a CaP layer on the sur-
face of SEVA-C after 15 days in SBF, exhibiting a
nanocrystalline needle-like structure, as presented in Figure
3(a, b). After incorporating the lowest concentrations stud-
ied of sodium clodronate, that is, 0.064 and 0.32 mg/mL,
the CaP crystallites did not present any observable modifi-
cation in their morphology. Therefore, the micrographs pre-
sented in Figure 3(a,b) are representative of the obtained
morphologies in these cases. When incorporating the high-
est studied concentrations of the BP (8 and 16 mg/mL),
well-defined spicule crystallites started to grow on the sur-
face of the CaP layer, as it can be visible by examining
Figure 3(c,d), for the case where a solution containing
8 mg/mL was used. By performing localized EDS, it was
possible to confirm that the elemental composition of these
structures exhibited a high content in Cl, which is assigned
to sodium clodronate (data not shown). On the other hand,
by observing the surface of the CaP layer in greater detail
[Figure 3(d)], it is also possible to find a modification in its
morphology. The resulting CaP crystals present a more
‘‘worm-like’’ morphology when comparing with the origi-
nal ‘‘needle-like’’ shape [Figure 3(b)]. This modification
can be attributed to a partial dissolution at the surface of
the CaP layer in the presence of the solutions containing
high concentrations of sodium clodronate (by calcium
depletion) and further reprecipitation under these new con-
ditions, which differ from those present in SBF in terms of
composition, ionic strength, and buffer capability. On the
other hand, because of its high affinity for Ca compounds
(especially to CaPs25,26), the chemical incorporation of the
drug onto the CaP structure, to a certain extent, is also pre-
dictable, causing dimensional rearrangements.
In Figure 5 is plotted the FTIR spectra performed on the
surface of SEVA-C before and after growing an CaP layer
and after incorporating the highest doses studied of sodium
clodronate. Again, by this technique, it was not possible to
detect the presence of BP in the samples treated with the
lowest concentrations of the drug. The IR spectrum of so-
dium clodronate powder is also presented as a reference for
identifying its characteristic peaks.
SEVA-C presents !!C!!O!!C!! bands at 1015–1140
cm21, which are characteristic of the glycosidic bonds
from starch.50,51 After coating the biomimetic layer, it is
possible to detect the typical bands of CaPs. The bands at
864, 1406, and 1434 cm21 result from the presence of car-
bonate (CO3
22) chemically incorporated in the CaP lat-
tice.52 These bands clearly indicate that a carbonated CaP
was formed, as it is found in bone apatite and as reported
for other biomimetic coating methods.13,53 The bands at
578 and 598 are assigned to the m4 bending mode of the
O!!P!!O bonds in the apatite, indicating some degree of
crystallinity. The band at 1012 cm21 indicates the m3
stretching mode of P!!O bonds.52 When sodium clodronate
is present, besides the major P!!O bond attributed to the m3
vibration of !!PO4, additional bands attributed to the same
Figure 4. EDS spectra showing the evolution of the elemental
composition of the apatite layers with increasing doses of sodium
clodronate.
Figure 5. FTIR-ATR spectra of SEVA-C before and after forming
an apatite layer and after the incorporation of 8 and 16 mg/mL
of sodium clodronate. Sodium clodronate powder was used as
reference.
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type of bonds are detected at 968, 1060, 1102, and 1122
cm21. The crystallites newly formed on the CaP layer and
detected by SEM can then be assigned to the precipitation
of the sodium clodronate.
Figure 6 presents the typical XRD patterns for the sur-
face of SEVA-C samples before and after growing the CaP
layers and for the same layers after incorporating sodium
clodronate at the highest studied doses. The profile of pure
sodium clodronate powder was also acquired and is, herein,
presented as a reference pattern.
SEVA-C diffraction profile presents two characteristic
broad peaks, detected at 2y 5 128 and 2y 5 208, assigned
to its crystalline phases.51 After growing the biomimetic
layers on its surface, it is possible to detect the two main
characteristic peaks attributed to HA (JCPDS card 9-432).
The peak at 2y 5 268 is assigned to (002) plane in the CaP
crystalline lattice. Another important diffraction peak is
detected around 2y 5 328 and is related to the overlapping
of planes (211), (112), and (300). This broad peak indicates
that the CaP structure is composed by small crystallites.
Similar XRD profile was obtained after adding sodium
clodronate at 0.064 and 0.32 mg/mL to the coatings. In this
way, XRD technique was not suitable for detecting such
low amounts of the drug in the coating. However, when
incorporating the drug at concentrations of 8 and 16 mg/
mL, several other strong reflections can be detected, as pre-
sented in Figure 5. This indicates the presence of a new
crystalline phase. These peaks can be well correlated with
the diffraction pattern of the drug. Nevertheless, differences
between both spectra can be detected, such as the appear-
ance of an intense peak at 2y 5 88 and a shift left of the
majority of the diffraction peaks. This result indicates that
sodium clodronate crystals have suffered a dimensional
rearrangement during crystallization at the surface of the
coating.
Microhardness
Figure 7 shows the microhardness of SEVA-C surface and
of the coatings as function of the increasing concentrations
of sodium clodronate. For the concentrations of 8 and 16
mg/mL, it was not possible to obtain consistent results
because of the high variability of roughness caused by the
sodium clodronate crystal spicules at the surface of the
CaP coating [as presented in Figure 3(c,d)].
After coating SEVA-C samples with the biomimetic
CaP layer, the microhardness increased from 12 to around
15 MPa. When incorporating sodium clodronate at concen-
trations from 0.064 to 0.32 mg/mL, an increase is observed
to values up to 22 MPa. In this way, the microhardness
increases significantly with increasing concentration, indi-
cating that the drug will influence the mechanical features
of the coating. Sodium clodronate in the form of a salt eas-
ily precipitated in the surface and in the pores of the CaP
coating, contributing to the structure reinforcement.
Dissolution of Ca and P
It is important to investigate the solubility of the CaP
layers because they will dictate the release profile of the
drug incorporated into it. In Figure 8 are plotted the disso-
lution profiles of Ca and P from the studied CaP coatings
immersed in the different media: a solution buffered to
pH 7.4 and another buffered to pH 3. This last solution
Figure 6. TF-XRD spectra of SEVA-C before and after forming an
apatite layer and after the incorporation of 8 and 16 mg/mL of
sodium clodronate. Sodium clodronate powder was used as refer-
ence. * SEVA-C; l Apatite; ~ Sodium clodronate.
Figure 7. Microhardness of the samples with different concentra-
tions of sodium clodronate in the CaP coatings. The continuous line
represents the average corresponding to the microhardness at the
level of the bulk substrate (uncoated sample).
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replicates the worst in vivo circumstance resulting from the
osteoclasts’ activity.
When analyzing the dissolution profiles of Ca and P
from the CaP coatings, one can observe that for the studied
solutions, different dissolution kinetics are observed. The
dissolution rates depend heavily on the pH because CaPs
are more soluble in acidic than in neutral conditions.27,54
As expected, when comparing the two dissolution media,
the CaP coatings dissolve at a higher rate when immersed
in the acidic solution, at pH 3. Nevertheless, the dissolution
characteristics of CaPs are governed by a large number of
other factors that are related either with the in vitro solu-
tion environment or with the properties of the material. In
addition to the pH, the environmental factors include the
type and concentration of the buffered or unbuffered solu-
tions, the degree of saturation, ionic strength, and so forth;
the material properties include chemical composition,
crystallinity, crystal particle size, density, and so forth.55
By comparing the dissolution profiles of Ca at pH 7.4
[Figure 8(a)], it is possible to observe that the trend of the
curves is quite similar, independent of the amount of drug
present in the CaP coating. Because the dissolution kinetics
was not significantly altered with the presence of the drug,
it means that the coating stability was not compromised.
When concerning the dissolution profile of P at pH 7.4
[Figure 8(b)] this trend is also present, with exception to
the case were 8 mg/mL of sodium clodronate was incorpo-
rated in the coating. In this case, the amount of P detected
results not only from the dissolution of the CaP coating but
also from the release of sodium clodronate, which has con-
tributed significantly to the total P measured. The dissolu-
tion rate of Ca and P is higher during the first 24 hours.
This can be correlated with nature of the CaP coatings. In
a dissolution study by Zhang et al.,56 using the same Tris–
HCl solution, it has been clearly demonstrated that at an
early stage of the dissolution, the process is governed by
the morphology, crystallinity, and crystal size of the CaP
layers. Because the CaP coatings are constituted by small
crystallites, there will be a high surface contact area with
the solution (the specific area), which will favor the disso-
lution process. With time, the dissolution rate decreases
and other factors became rather important, as for example,
the ionic product of the surrounding medium. The increase
of dissolved Ca and P in solution will favor some degree
of reprecipitation, which can also contribute to the decrease
in the dissolution rate.
The dissolution profiles of Ca and P at pH 3 [Figure
8(c,d)] indicate that after 24 hours, the CaP coatings were
completely dissolved. Furthermore, in this case, the dissolu-
tion kinetics was not significantly altered with the presence
of sodium clodronate, which means that the coating initial
stability was preserved. Again, in case of the coatings
incorporating 8 mg/mL of sodium clodronate, the released
amount of P was higher.
Sodium Clodronate Release Profiles
The release profiles of sodium clodronate, incorporated at a
concentration of 8 mg/mL, in the two studied solutions are
plotted in Figure 9. The release profiles at concentrations
lower than this value were below the HPLC detection limit.
Figure 8. Dissolution profile of Ca and P in standard solutions buffered at (a,b) at pH 7.4 and (c,d) at pH 3.
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The release profile of sodium clodronate obtained in the
solution buffered at pH 7.4 [Figure 9(a,b)] follows the
same trend of the P release presented in Figure 8(b).
Around 30% of the drug is released in the first 24 hours.
After 14 days, 70 % of the drug was released, the remain-
der being incorporated in the structure of the CaP layer,
possibly due to a reprecipitation phenomenon.56
The sodium clodronate release profile at pH 3 [Figure
9(c,d)] indicates that the entire drug is released in the
first 24 hours of the experiment. Again, this result is
consistent with the correspondent dissolution profile of P
presented in Figure 8(d). At this time period, all the CaP
is completely dissolved. The drastic effect of this solu-
tion simulates the osteoclastic digestion, which, in vivo,
would be characterized by the release of citric acid in
the surface of the coating and the formation of the
so-called resorption pits.57 In this extreme situation, the
stability of the CaP is very low, leading to total dissolu-
tion. Further in vitro osteoclasts studied will help to
determine the stability of the CaP coatings in the pres-
ence of these cells.
Preliminary Evaluation of the
Cell Adhesion and Proliferation
Figure 10 presents SEM micrographs of the morphology
of the osteoblasts after 3 days of seeding as function of
time and concentration of sodium clodronate. In Figure
11 are plotted the results concerning the cell viability
(MTS) for the different times and concentrations of BP
studied.
The incorporation of sodium clodronate on the CaP
coating had a significant influence on the adhesion of the
cells onto its surface. This can be clearly observed in the
example presented in Figure 10 after 3 days of culture,
when 0.064 and 0.32 mg/mL were present in the CaP coat-
ing. With the presence of the BP incorporated in the CaP
coating at these doses, the cells presented a more flatten
morphology, reflecting higher number of adhesion points to
the surface. This behavior indicates a superior affinity
to this type of surface compared with the cells that adhered
to the CaP-coated surfaces but without the BP. For the
higher concentrations of drug used, that is, 8 and 16 mg/
mL, a decrease in the cell number was observed, and the
cells presented a more round morphology (data not shown),
indicating that at these levels sodium clodronate induced a
toxic behavior.
Based on the MTS assay (Figure 11), BP stimulated cel-
lular proliferation, and this effect was strongly dependent
on the dose and on the coating type. The effect of the drug
followed a sigmoid curve, causing inhibition of cellular
activity at the highest dose studied and peaked at 0.32 mg/
mL. Along the time, it was also observed that a sigmoid
curve peaked at day 5 and decreased at day 7.
Figure 9. Calibration curves of sodium clodronate and respective release profiles in (a) a solution
buffered at pH 7.4 and (b) a solution buffered at pH 3.
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DISCUSSION
Sodium clodronate could be successfully incorporated, at
different doses, in the structure of a biomimetic CaP layer
formed by a sodium silicate process. This initial study was
aimed at evaluating the effects of this BP (i) on the struc-
ture and in vitro stability of the CaP layers; and (ii) on the
growth and function of a human osteoblast cell line,
because there is still little information available on the
interaction between BPs and this type of cells. In addition
to defining the minimum dose to be incorporated in the
CaP coating, it was also possible to detect a stimulatory
effect of the osteoblastic activity when the ideal dose was
incorporated.
The properties and composition of the produced biomi-
metic CaP layers were tailored in previous studies15,58 and
have dictated the type of interaction with the drug and its
loading efficiency. In fact, the choice of the adequate CaP
to be used as a carrier for the drug is an important aspect
for an effective incorporation. The processing route for
obtaining the CaP is also a relevant aspect. Although
known to be stable under most chemical conditions, BPs
decompose at relatively low temperatures (2008C),59 which
makes most coating techniques, as for example plasma-
spray or sol–gel, inapplicable for coprecipitation. In these
cases, a postloading methodology has been an adopted
solution,60–62 which showed limited success. Because of
the more crystalline and dense nature of the CaP coatings,
the BP could only be incorporated at the outermost surface.
Some authors62,63 have tried to overcome this problem by
coprecipitating carbonated CaP layers with the BP over
their highly crystalline CaP substrates. In a recent study,
Peter et al.63 proposes to coprecipitate pamidronate with a
CaP coating from an SBF solution onto a preformed
plasma-sprayed coating. The efficiency of this method was,
however, limited. Plasma-sprayed HA presents a less reac-
tive surface and usually a more compact structure when
comparing with the currently proposed coating technique.
Therefore, the drug was only incorporated in the layer of
carbonated CaP, which was more reactive to the drug. In a
study performed by Seshima et al.60 it was demonstrated
that the porosity (specific surface area) and crystal size of a
CaP have a profound influence in its solubility and conse-
quently in the ability to incorporate/release the BPs. CaPs
with lower crystal size and higher specific surface area will
present a higher solubility as well as a higher ability for
incorporating the BP. This effect was also experienced by
Figure 10. SEM micrographs osteoblast-like cells (SaOs-2) after 3 days in culture of showing the
adhesion onto the surfaces of the apatite coatings: (a,b) without incorporation of sodium clodronate,
and after incorporation of sodium clodronate at (c) 0.064 mg/mL and (d) 0.32 mg/mL.
Figure 11. Quantification of the cell viability after different periods
of culture on apatite coatings as function of sodium clodronate
content.
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Josse et al.61 when incorporating the BP zoledronate onto
different CaP compounds. By using mainly 31P NMR spec-
troscopy, two different association modes have been
observed, according to the nature of the CaP support and/
or the initial concentration of the zoledronate solution.
b-Tricalcium phosphate (b-TCP) and mixtures of HA and
b-TCP seem to promote zoledronate-containing crystal for-
mation. On the other hand, at low concentrations, calcium-
deficient CaPs seem to undergo chemisorption of the drug
through a surface adsorption process, due to PO3 for PO4
exchange.
In our study, we were able to promote the interaction of
different amounts of sodium clodronate with a biomimetic
CaP layer because of its partially amorphous and nanocrys-
talline nature. It was possible to detect the presence of this
drug by SEM/EDS, TF-XRD, and FTIR analysis when
incorporated at concentrations of 8 and 16 mg/L. However,
for these high concentration levels, the majority of the drug
detected resulted from the precipitation of crystal spicules
of the drug at the surface of the CaP layer during drying.
Nevertheless, at higher magnifications, it is possible to
detect a modification of the CaP nanocrystalline structure,
indicating that a structural rearrangement has occurred
probably due to a dissolution and reprecipitation phenom-
ena in the presence of the drug.56 However, the extent of
this modification did not significantly alter the overall
structural stability of the CaP coatings, as it can be clearly
indicated by the similar dissolution profiles at pHs 7.4 and
3. When 8 mg/mL of BP is incorporated in the CaP coat-
ing, after 14 days of release, around 30% of the drug
remained in its structure, indicating that a chemical interac-
tion is most certainly occurring because, like other BPs,
sodium clodronate has a great affinity to Ca ions by form-
ing complexes.25,26,64 The type of interactions between this
drug and CaP layer will be further investigated by NMR
studies.
At lower concentrations (0.064 and 0.32 mg/mL),
sodium clodronate was not detected by the techniques men-
tioned earlier. Nevertheless, it was able to influence the
mechanical properties of the coating toward an increase of
the microhardness of the surface. It can be extrapolated
that the presence of the drug at low amounts will influence
the mechanical environment that the cells will feel when in
contact with the material together with the new chemical
environment. In fact, sodium clodronate incorporated on
the CaP has influenced cellular proliferation. This effect
was strongly dependent on the dose incorporated, being
0.32 mg/mL of BP the ideal concentration for enhancing
cell viability.
Ganguli et al.65 demonstrated that the synthesis of
DNA, protein, and collagen was enhanced in osteoblasts
when cultured on CaP surfaces coated with clodronates
or pamidronates, proving to have a potent proliferative
effect on osteoblasts. Our preliminary studies with SaOs-
2 cells seem to indicate a similar response to BPs in
terms of cell proliferation. Without minimizing the influ-
ence of other factors, these results, although still noncon-
clusive, presented a good reproducibility and a good
correlation between the presence of sodium clodronate on
the CaP coatings and cell morphology (Figure 10) and
viability (Figure 11). The stimulatory effect of this drug,
together with the potential for inhibiting bone resorption
via osteoclasts, without altering the structure of the CaP,
can make this approach very effective for improving
implant–bone integration, and moreover, in applications
were regeneration of the tissue is required, as in tissue
engineering TE applications. This preliminary results en-
courage further studies, namely to test the osteoclastic
activity, that will be performed in the near future. Fur-
thermore, because of the physiological working condi-
tions (T, pH) of this biomimetic methodology, new
design strategies are currently being considered with the
aim of coprecipitating this drug at an early stage of the
coating process to obtain BP-containing layers for long-
term controlled release. It is foreseen that the coatings
incorporating their therapeutic agent can, for instances,
be produced on degradable polymeric carriers for the
treatment of specific bone diseases regulating the equilib-
rium on osteoblastic/osteoclastic activity in the direction
of a regenerative effect.
CONCLUSIONS
Sodium clodronate could be successfully incorporated, at
different doses, in the structure of a biomimetic CaP layer
formed by a sodium silicate process. At lower concentra-
tions, sodium clodronate was able to influence the mechani-
cal properties of the coating towards an increase of the
microhardness of the surface. The presence of the drug in
low amounts has influenced the mechanical environment
that the cells feel when in contact with the material together
with the new chemical environment. This effect was strongly
dependent on the dose incorporated, being 0.32 mg/mL of
BP the ideal concentration for enhancing cell viability and
osteoblastic profile. This stimulatory effect, together with
the potential for inhibiting bone resorption, without altering
the structure of the CaP, can make this approach very effec-
tive for improving implant–bone integration, and moreover,
in applications were regeneration of the tissue is required, as
in tissue engineering TE applications.
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